Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European journal of medicinal chemistry

• Publication date

  2017-08-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2017.04.068PMID 28505536
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.

  2016cited by this paper
• Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.

  2016cited by this paper
• Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.

  2016cited by this paper
• Mechanisms and regulation of endothelial VEGF receptor signalling

  2016cited by this paper
• Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.

  2016cited by this paper
• Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.

  2016cited by this paper
• FDA-approved small-molecule kinase inhibitors.

  2015cited by this paper
• Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.

  2015cited by this paper
• Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents.

  2014cited by this paper
• A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.

  2014cited by this paper
• Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

  2014cited by this paper
• Synthesis, Biological Evaluation, and Docking Studies of New 2‐Furylbenzimidazoles as Anti‐Angiogenic Agents: Part II

  2014cited by this paper
• Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

  2012cited by this paper
• Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

  2012cited by this paper
• Vascular endothelial growth factor receptor-2 in breast cancer.

  2010cited by this paper
• A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis.

  2010cited by this paper
• Through the "gatekeeper door": exploiting the active kinase conformation.

  2010cited by this paper
• NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities

  2010cited by this paper
• Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

  2010cited by this paper
• Screening for allosteric kinase inhibitors in high-throughput: A novel fluorescence approach for detecting DFG-out kinase inhibitors

  2009cited by this paper
• Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

  2009cited by this paper
• Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.

  2009cited by this paper
• VEGF receptor protein-tyrosine kinases: structure and regulation.

  2008cited by this paper
• Mechanisms of angiogenesis

  2008cited by this paper
• Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.

  2007cited by this paper
• Su-11248 Sugen.

  2004cited by this paper
• Are tumours angiogenesis‐dependent?

  2004cited by this paper
• Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

  2004cited by this paper
• UCSF Chimera—A visualization system for exploratory research and analysis

  2004cited by this paper
• GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.

  2004cited by this paper
• Tyrosine kinases as targets in cancer therapy – successes and failures

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• [Angiogenesis in cancer].

  2002cited by this paper
• Tumor angiogenesis: past, present and the near future.

  2000cited by this paper
• Cell proliferation and cancer.

  1998cited by this paper
• Receptor tyrosine kinases as targets for inhibition of angiogenesis

  1997cited by this paper
• Mechanisms of angiogenesis

  1997cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

  1991cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• [New heterocyclic derivatives of benzimidazole with germicidal activity].

  1982cited by this paper
• A new synthesis of benzimidazoles and aza‐analogs

  1965cited by this paper
• A new synthesis of adenine and 4-aminoimidazole-5-carboxamide

  1965cited by this paper

• New Benzimidazole Scaffolds Tagged With Isatin/Thiourea Motifs as Anti‐Cancer Agents: Promising Approach for VEGFR‐2 Inhibition

  2026cites this paper
• <i>In-silico</i> Study on Pharmacokinetic Properties and VEGFR-2 Binding of Quininib Through Molecular Docking

  2026cites this paper
• Therapeutic Insights of Indole Scaffold‐Based Compounds as Protein Kinase Inhibitors

  2025cites this paper
• Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer

  2025cites this paper
• Advances in VEGFR Inhibitors: A Comprehensive Review of Novel Anticancer Agents.

  2025cites this paper
• Ultrasound-assisted extraction of antioxidative peptides from tomato (Solanum lycopersicum) and their anti-angiogenic potential via molecular docking

  2025influential citation
• Design, Synthesis, In Silico and In Vitro Studies Urea Derivatives as VEGFR-2 Inhibitors

  2025cites this paper
• Benzimidazole-based hybrids as inhibitors of EGFR/VEGFR-2 and their combinations with other enzymes: design, synthesis, and activity.

  2025cites this paper
• Bicyclic 2-aminopyrimidine derivatives as potent VEGFR-2 inhibitors and apoptosis Inducers: Structure-Guided design, synthesis, anticancer assessment, and in-silico exploration.

  2025cites this paper
• Sulfonamides a Promising Hit for Cancer Therapy Through VEGFR-2 Inhibition

  2025influential citation
• Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR/VEGFR-2 inhibition.

  2025cites this paper
• Recent progress in the exploitation of anti-cancer small molecules targeting angiogenesis

  2025influential citation
• Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations

  2025influential citation
• Rational design, docking, syntheses, ADMET and cytotoxicity assessments of iodoquinazoline derivatives as inhibitors of EGFRT790M and VEGFR-2

  2025cites this paper
• Structural effects of the carboxylate anion on Ru-catalyzed C—H arylation of (hetero)aromatic substrates containing N-donor directing group

  2024cites this paper
• In silico insights into design of novel VEGFR-2 inhibitors: SMILES-based QSAR modelling, and docking studies on substituted benzo-fused heteronuclear derivatives

  2024cites this paper
• Novel Thiazolidine‐2,4‐Dione Derivatives as Potential VEGFR‐2 Inhibitors: Synthesis, Biological Testing, and in Silico Studies

  2024cites this paper
• Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma.

  2024cites this paper
• Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors

  2024cites this paper
• The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy.

  2024cites this paper
• Biological and in silico investigation of isolated novel bioactive compound from Conocarpus lancifolius

  2024cites this paper
• Challenging the anticolorectal cancer capacity of quinoxaline-based scaffold via triazole ligation unveiled new efficient dual VEGFR-2/MAO-B inhibitors.

  2024cites this paper
• Targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Latest Insights on Synthetic Strategies

  2024cites this paper
• Harnessing potential COX-2 engagement for boosting anticancer activity of substituted 2-mercapto-4(3H)-quinazolinones with promising EGFR/VEGFR-2 inhibitory activities.

  2024cites this paper
• New quinazoline-N-4-fluorophenyl derivatives as potential anticancer agents: Discovery of a promising dual EGFR/VEGFR-2 inhibitor

  2024cites this paper
• A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors.

  2024cites this paper
• Promoting Apoptosis in MCF-7 Cells via ROS Generation by Quinolino-triazoles Derived from One-Pot Telescopic Synthesis.

  2024cites this paper
• Novel 1,2,3-triazole derivatives containing benzoxazinone scaffold: Synthesis, docking study, DFT analysis and biological evaluation

  2024cites this paper
• Design, synthesis, and in silico insights of novel N'-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors.

  2024cites this paper
• S-Alkylated quinazolin-4(3H)-ones as dual EGFR/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study

  2024cites this paper
• Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFRT790M: Molecular docking, ADMET, design, and syntheses

  2024cites this paper
• Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity

  2024cites this paper
• Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation

  2024cites this paper
• New sulfonamide-based glycosides incorporated 1,2,3-triazole as cytotoxic agents through VEGFR-2 and carbonic anhydrase inhibitory activity

  2024cites this paper
• 3-hydroxy-3-(1H-indol-3-yl)-5-nitrooxindole and derivative

  2024cites this paper
• Antioxidant potential of betel fruits (Piper betle) extract and molecular docking study of betel fruit bioactive compounds against human ROS kinase free radical receptors

  2023cites this paper
• Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations.

  2023cites this paper
• Synthesis, Characterizations, and Quantum Chemical Investigations on Imidazo[1,2-a]pyrimidine-Schiff Base Derivative: (E)-2-Phenyl-N-(thiophen-2-ylmethylene)imidazo[1,2-a]pyrimidin-3-amine

  2023cites this paper
• Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

  2023cites this paper
• Novel N-Arylmethyl-aniline/chalcone hybrids as potential VEGFR inhibitors: synthesis, biological evaluations, and molecular dynamic simulations

  2023cites this paper
• Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents.

  2023cites this paper
• Revealing the contributions of DFT to the spectral interpretation for an amino benzoyl thiourea derivative: Insights into experimental studies from theoretical perspectives, and biological evaluation

  2023cites this paper
• Albendazole repurposing on VEGFR-2 for possible anticancer application: In-silico analysis

  2023cites this paper
• New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity.

  2023cites this paper
• Novel VEGFR‐2 Kinase Inhibitors as Anticancer Agents: A Review Focusing on SAR and Molecular Docking Studies (2016–2021)

  2023cites this paper
• Advances in antitumor research of HIF-1α inhibitor YC-1 and its derivatives.

  2023cites this paper
• Discovery of New Quinoxalines as Cytotoxic Agents: Design, Synthesis and Molecular Modeling

  2023cites this paper
• CH-alkylation of furan derivatives under photoinduced Pd catalysis

  2023cites this paper
• In silico ADMET, docking, anti-proliferative and antimicrobial evaluations of ethanolic extract of Euphorbia dendroides L.

  2022cites this paper
• Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside

  2022cites this paper
• New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation

  2022cites this paper
• DDDT_A_344750 587..606

  2022cites this paper
• Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents

  2022cites this paper
• Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation.

  2022cites this paper
• The Design and Synthesis of a New Series of 1,2,3-Triazole-Cored Structures Tethering Aryl Urea and Their Highly Selective Cytotoxicity toward HepG2

  2022cites this paper
• Synthesis, Biological Evaluation, and Molecular Docking of New Benzimidazole-1,2,3-Triazole Hybrids as Antibacterial and Antitumor Agents

  2022cites this paper
• Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.

  2022cites this paper
• Ruthenium(II)-catalyzed C(3)–H arylation of furan moiety in fuberidazole derivatives

  2022cites this paper
• Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy

  2022cites this paper
• Benzimidazole‐1,3,4‐Oxadiazole Hybrids: Synthesis, Anticancer Evaluation, Docking and DFT Studies

  2022cites this paper
• 2,4‐Bis(2‐( E )‐arylidenehydrazinyl)quinazolines: Expeditious Synthesis, Characterization, Antiproliferative Effects against Breast Cancer Cell Line and Molecular Docking Studies

  2022cites this paper
• Synthesis, Antimicrobial, Antiproliferative, and Docking Studies of 1,3,4-Oxadiazole Derivatives Containing Benzimidazole Scaffold

  2022cites this paper
• Phenotypic Discovery of Triazolo[1,5-c]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype.

  2022cites this paper
• Synthesis of Palladium‐Catalysed C−C Bond Forming 5‐Chloro Quinolines via Suzuki‐Miyaura Coupling; Anti‐Pancreatic Cancer Screening on PANC‐1 Cell Lines

  2022cites this paper
• Benzimidazol-Tiyadiazol Türevlerinin Sentezi, Karakterizasyonu, Antioksidan ve Antikanser Çalışmaları

  2022cites this paper
• New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.

  2021cites this paper
• JBSED-03-2021-0023_proof 182..196

  2021cites this paper
• In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity

  2021cites this paper
• Synthetic strategy and structure–activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review

  2021cites this paper
• Applying Nanotechnology in the Synthesis of Benzimidazole Derivatives: A Pharmacological Approach

  2021cites this paper
• Design and synthesis of new pyrazolylbenzimidazoles as sphingosine kinase-1 inhibitors

  2021cites this paper
• Political ties and corporate performance: why efficiency matters?

  2021cites this paper
• Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.

  2021cites this paper
• Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers

  2021cites this paper
• Recent Anti‐angiogenic Drug Discovery Efforts To Combat Cancer

  2021cites this paper
• Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor

  2021cites this paper
• Pyridine‐derived VEGFR‐2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking

  2021cites this paper
• Recent Developments Towards Synthesis of (Het)arylbenzimidazoles

  2021cites this paper
• Design and synthesis of new pyrazolylbenzimidazoles as sphingosine 1-kinase inhibitors

  2021cites this paper
• Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers

  2021cites this paper
• Synthesis, crystal structure, and ADME prediction studies of novel imidazopyrimidines as antibacterial and cytotoxic agents

  2020cites this paper
• Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.

  2020cites this paper
• Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.

  2020cites this paper
• 2-Ylidene-1,3-thiazolidines and their nonhydrogenated analogs: methods of synthesis and chemical properties

  2020cites this paper
• Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.

  2020cites this paper
• Synthesis, Crystal Structures, Interaction with DNA, Cytotoxicity, and Apoptosis Studies of Co(II), Cd(II) Complexes Bearing Pyrazine-2,3-dicarboxylic Acid

  2020cites this paper
• Versatile mechanisms of 2-substituted benzimidazoles in targeted cancer therapy

  2020cites this paper
• Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.

  2020cites this paper
• One-pot synthesis, crystal structure, hirshfeld, DFT and anticancer study of ethyl 2-(3-fluoro-4-methylphenyl)-1-propyl-1H-benzo[d]imidazole-5-carboxylate

  2020cites this paper
• Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles

  2020cites this paper
• Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multiangiokinase inhibitors targeting breast cancer

  2020cites this paper
• Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.

  2019cites this paper
• Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs.

  2019cites this paper
• Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.

  2019cites this paper
• New 2,4‐disubstituted‐2‐thiopyrimidines as VEGFR‐2 inhibitors: Design, synthesis, and biological evaluation

  2019cites this paper
• Recent Progress of benzimidazole hybrids for anticancer potential.

  2019cites this paper
• In vitro MAO-B Inhibitory Effects of Citrus trifoliata L. Fruits Extract, Self-Nano-Emulsifying Drug Delivery System and Isolated Hesperidin: Enzyme Assay and Molecular Docking Study

  2019cites this paper
• Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.

  2019cites this paper
• Crystal structure, non-covalent interaction and molecular docking studies of 2-{[2-phenylsulfonyl)hydrazinylidene]methyl}benzoic acid and its dysprosium catalysed cyclized product: 2-(phenyl-sulfonyl)phthalazin-1(2H)-one

  2019cites this paper
• Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.

  2019cites this paper